RTP Mobile Logo
RTP TV — Melanoma and Nonmelanoma Skin Cancers
Released April 2013

This online educational course explores topics relevant to the treatment of melanoma and nonmelanoma skin cancers. Originally held on April 11, 2013, this program features Drs Keith T Flaherty and Anna C Pavlick. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE

    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of melanoma and nonmelanoma skin cancers.

    OVERVIEW OF ACTIVITY

    Melanoma and nonmelanoma skin cancers (basal cell carcinoma [BCC] and cutaneous squamous cell cancer [SCC]), taken together, likely represent the most prevalent form of human cancer. Fortunately, the vast majority of skin cancers present as minimally invasive BCC and SCC and, as such, are highly curable with local treatment alone. However, in rare instances, these characteristically indolent lesions do progress and necessitate systemic intervention with the support of limited randomized clinical evidence. In contrast, malignant melanoma is the most aggressive form of skin cancer with a predilection toward distant metastases even when identified in the clinically early stages of disease. Thus, melanoma and nonmelanoma skin cancers are quite distinct entities, each posing unique challenges to the oncology community. This program uses a review of recent publications and presentations, faculty cases and Q&A to assist medical oncologists, hematology-oncology fellows and other healthcare providers with the formulation of up-to-date clinical management strategies for skin cancer.


    LEARNING OBJECTIVES
    • Provide a summary of the scientific rationale and research results that support the activity of novel chemotherapeutic and targeted agents and immunotherapeutic strategies in patients with melanoma, and appraise their clinical applicability.
    • Consider the oncogenic mutations that play an important role in the etiology and pathogenesis of melanoma when formulating treatment strategies using biologic therapies.
    • Recognize the cutaneous and other commonly observed adverse events associated with BRAF-targeted therapy for patients with advanced-stage melanoma, and employ management strategies to minimize and/or manage these side effects.
    • Recognize immune-related adverse events associated with anti-CTLA-4 antibody therapy, and offer supportive management strategies to minimize and/or manage these side effects.
    • Assess recent Phase III data evaluating nab paclitaxel versus dacarbazine in patients with treatment-naïve metastatic melanoma, and revisit the role of cytotoxic chemotherapy in the management of the disease.
    • Explain the fundamental role of hedgehog signaling in BCC pathogenesis and treatment.
    • Recall the design of ongoing clinical trials in advanced melanoma and nonmelanoma skin cancer, and consent or refer eligible patients for study participation.
    ACCREDITATION STATEMENT
     
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CREDIT DESIGNATION STATEMENT
     

    CME credit is no longer available for this issue


    HOW TO USE THIS CME ACTIVITY
     
    This CME activity consists of a video component. To receive credit, the participant should watch the video.

    CME credit is no longer available for this issue


    CONTENT VALIDATION AND DISCLOSURES
     
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Keith T Flaherty, MD
    Director, Henri and Belinda Termeer Center for Targeted Therapies
    Massachusetts General Hospital Cancer Center
    Associate Professor, Harvard Medical School
    Director of Developmental Therapeutics
    Boston, Massachusetts

    Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Eisai Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Sanofi; Consulting Agreements: Genentech BioOncology, GlaxoSmithKline, Momenta Pharmaceuticals Inc, Otsuka Pharmaceutical Co Ltd, Roche Laboratories Inc; Contracted Research: Novartis Pharmaceuticals Corporation, Sanofi.

    Anna C Pavlick, MS, DO
    Associate Professor of Medicine and Dermatology
    Director, NYU Melanoma Program
    Director, NYU Clinical Trials Office
    Assistant Director for Clinical Research and Education
    New York University Langone Medical Center
    New York, New York

    Paid Research: Bristol-Myers Squibb Company, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer Inc; Speakers Bureau: Bristol-Myers Squibb Company, Genentech BioOncology.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.
     
    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewersfor Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology and Prometheus Laboratories Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

Acknowledge and close

Watch Video
(WiFi is recommended for best performance):